Advantage Alpha Capital Partners LP Alkermes Plc. Transaction History
Advantage Alpha Capital Partners LP
- $337 Million
- Q2 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Alkermes Plc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 17,322 shares of ALKS stock, worth $541,485. This represents 0.15% of its overall portfolio holdings.
Number of Shares
17,322
Previous 21,357
18.89%
Holding current value
$541,485
Previous $705,000
29.79%
% of portfolio
0.15%
Previous 0.2%
Shares
7 transactions
Others Institutions Holding ALKS
# of Institutions
395Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$910 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$578 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$314 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$257 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$200 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.13B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...